Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Lung Cancer
•
Thoracic Malignancies
•
Medical Oncology
Is there a role for pemetrexed in the treatment of metastatic adenosquamous NSCLC?
Related Questions
In patients with EGFR mutant L858R stage III NSCLC who are unresectable due to multistation N2 disease, would you consider upfront osimertinib over definitive intent CCRT?
How would you manage a left sided triple negative breast cancer with a concurrent left sided locally advanced non-small cell lung cancer?
Would you add ALK-targeted therapy for patients with EGFR L858R-mutant lung adenocarcinoma who progress on targeted therapy and develop a concomitant STRN-ALK fusion?
Would you ever consider repeating chemoradiation for patients with locally recurrent small cell lung cancer after prior chemoradiation for LS-SCLC?
Will you consider definitive concurrent chemoradiation for stage IV lung adenocarcinoma with metastasis limited to an internal mammary lymph node?
Is dyspnea without radiation pneumonitis a side effect of lung radiation?
What are your top takeaways in Thoracic Cancers from ASCO 2023?
Would you offer a different ALK inhibitor to a patient receiving alectinib who had decompensation of liver function in the setting of preexisting cirrhosis?
What is your approach for an RA patient with lung cancer who is starting immunotherapy?
How do you schedule IV/PO Dexamethasone if giving immunotherapy concurrently with chemotherapy in patients with NSCLC?
